How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bone-marrow-suppression-due-to-folic-acid-antagonism.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bone Marrow Suppression due to Folic Acid Antagonism — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bone Marrow Suppression due to Folic Acid Antagonism (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bone Marrow Suppression due to Folic Acid Antagonism, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Fusilev	Levofolinic acid	Spectrum Pharms	Folate Analog		2008-01-01
Fusilev	levoleucovorin	Acrotech Biopharma	Folate Analog		2008-01-01
Wellcovorin	leucovorin	Pfizer Japan Inc	Folate Analog	Dihydrofolate reductase	1952-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Acrotech Biopharma · 1 drug in Bone Marrow Suppression due to Folic Acid Antagonism
Pfizer Japan Inc · 1 drug in Bone Marrow Suppression due to Folic Acid Antagonism
Spectrum Pharms · 1 drug in Bone Marrow Suppression due to Folic Acid Antagonism

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bone Marrow Suppression due to Folic Acid Antagonism:

Cite this brief

Drug Landscape (2026). Bone Marrow Suppression due to Folic Acid Antagonism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bone-marrow-suppression-due-to-folic-acid-antagonism. Accessed 2026-06-10.

Bone Marrow Suppression due to Folic Acid Antagonism full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing